Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

safe and generally well tolerated.

ITMN-191 (RG7227)

  • On November 3, results of INFORM-1 were presented at the meeting of the American Association for the Study of the Liver (AASLD). INFORM-1 is a Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with HCV. The study combined the oral NS3 protease inhibitor ITMN-191 and the oral nucleoside analog polymerase inhibitor RG7128. The results announced at AASLD focused on the recently completed final three cohorts of INFORM-1, consisting of higher-dose, twice-daily regimens:
    • The full dose combination of RG7128 1000mg and RG7227 900mg administered twice-daily without pegylated interferon or ribavirin for 13 days resulted in 88% of HCV-positive treatment-naive patients achieving HCV RNA below the lower limit of quantification (LLOQ; <43 IU/mL), and 63% of patients having HCV RNA below the lower limit of detection (LLOD; <15 IU/mL).
    • The same regimen in "null responders" resulted in 50% of patients with HCV RNA below LLOQ and 25% of patients with HCV RNA below LLOD.
    • No treatment-emergent resistance to RG7227 or RG7128 was observed in the study.
    • The all-oral, interferon-free combination showed promising safety and tolerability. No treatment-related serious adverse events (SAEs), dose reductions or discontinuations were reported in any patient in INFORM-1, including previously reported lower dose cohorts. The most commonly reported adverse events (AEs) were headache, nausea and diarrhea and these had a similar incidence to previously reported lower-dose cohorts.
  • Enrollment began in August for the company's Phase 2b study of ITMN-191 in combination with PEGASYS® (pegylated interferon) and COPEGUS® (ribavirin), the current standard of care in HCV. The Phase 2b trial will study both twice-daily (600mg a
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... COLUMBUS, Ohio, July 30, 2015 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... in the quarter. , Net earnings per diluted ... in the prior-year period. Adjusted EPS was $2.80 , ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
(Date:7/31/2015)... Indianapolis, Ind. (PRWEB) , ... August 01, 2015 , ... ... of the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 ... were invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being outside ... making July the most appropriate to be National Hot Dog Month. King Kullen honors ... next cookout different than the ones in the past. Celebrate National Hot Dog Month ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... NV (PRWEB) , ... July 31, 2015 , ... Well-known ... is now offering wedding cakes with custom designs, making life just a ... deliver beautifully designed wedding cakes for each customer who orders one. , The bakery ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), ... strategy and its unique niche in the drug development ... the latest generation of biotherapeutic technologies that can cure ... on prostate and breast cancers, GENova has acquired a ...
... , , MURRIETA, Calif., Sept. ... ABTTC Inc. division provides drug and alcohol rehabilitation and a ... of accreditation, announced today that Jerrod Menz, Forterus Vice President ... and Jim Fent, Executive Vice President, will be interviewed on ...
... ... Nursing Reference Center™ and Patient Education Reference Center™ Available online at www.ebscohost.com/flu . ... , ... (PRWEB) September 9, 2009 -- Concerns about Pandemic H1N1 and the upcoming flu season ...
... ... as well as cosmetic and sedation dentistry, announces the addition of it,s sister practice, ... ... Dentistry, led by Dr. Robert L. Williamson III is pleased to announce the addition ...
... Democratic National Committee Members To Gather September 10-12 at ... Highlight Meeting , , WASHINGTON, Sept. 9 ... meet this Thursday, September 10 through Saturday, September 12 at ... meeting on Friday, members will hear a major speech from ...
... JACKSONVILLE, Fla., Sept. 8 Sinapis Pharma announces that ... injury treatment data at the Rodman & Renshaw Annual Global Investment ... September 11, 2009, at 3:15 PM ET. Sinapis has discovered ... of an FDA-approved drug that will be in clinical development in ...
Cached Medicine News:Health News:GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum 2Health News:GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum 3Health News:Forterus Inc. Executives to Be Interviewed on VoiceAmerica 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 2Health News:EBSCO Publishing Makes Evidence-Based Flu Resources Freely Available 3Health News:Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 2Health News:Details of DNC Fall Meeting in Austin 2
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
... the Attain Prevail's steerable tip, along with ... to obtain the curve you need, when ... improved visualization of the cardiac venous anatomy, ... Telescoping - Adjust curve and reach ...
Attain CS Leads. Navigate minimally angled veins with no tortuosity....
Medicine Products: